BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2894309)

  • 1. Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator.
    Lijnen HR; Van Hoef B; Nelles L; Holmes WE; Collen D
    Eur J Biochem; 1988 Feb; 172(1):185-8. PubMed ID: 2894309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
    Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
    Eur J Biochem; 1988 Nov; 177(3):575-82. PubMed ID: 2973984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
    Lijnen HR; Van Hoef B; Nelles L; Collen D
    J Biol Chem; 1990 Mar; 265(9):5232-6. PubMed ID: 1969415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.
    Lijnen HR; Van Hoef B; De Cock F; Collen D
    Blood; 1989 May; 73(7):1864-72. PubMed ID: 2713507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
    Nelles L; Lijnen HR; Collen D; Holmes WE
    J Biol Chem; 1987 Apr; 262(12):5682-9. PubMed ID: 3106341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
    Dewerchin M; Lijnen HR; Van Hoef B; De Cock F; Collen D
    Eur J Biochem; 1989 Oct; 185(1):141-9. PubMed ID: 2530085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.
    Fleury V; Lijnen HR; Anglés-Cano E
    J Biol Chem; 1993 Sep; 268(25):18554-9. PubMed ID: 8103046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
    Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
    Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
    Lijnen HR; Li XK; Nelles L; Hu MH; Collen D
    Eur J Biochem; 1992 Apr; 205(2):701-9. PubMed ID: 1533368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
    Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
    Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
    Li XK; Lijnen HR; Nelles L; Hu MH; Collen D
    Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator.
    Lijnen HR; Piérard L; Reff ME; Gheysen D
    Thromb Res; 1988 Dec; 52(5):431-41. PubMed ID: 3146822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
    Holvoet P; Laroche Y; Lijnen HR; Van Cauwenberge R; Demarsin E; Brouwers E; Matthyssens G; Collen D
    J Biol Chem; 1991 Oct; 266(29):19717-24. PubMed ID: 1918077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
    Lijnen HR; Wnendt S; Schneider J; Janocha E; Van Hoef B; Collen D; Steffens GJ
    Eur J Biochem; 1995 Nov; 234(1):350-7. PubMed ID: 8529664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase mutant with better fibrin-specificity.
    Ma Z; Yu R; Hua Z; Zhu D
    Sci China C Life Sci; 1996 Oct; 39(5):523-33. PubMed ID: 9772355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
    Lijnen HR; Van Hoef B; Collen D
    Eur J Biochem; 1987 Dec; 169(2):359-64. PubMed ID: 2961562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
    Gurewich V; Pannell R; Broeze RJ; Mao J
    J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.